Clinical Trials Logo
  1. Home
  2. Herpes Zoster
  3. NCT03903237
  4. Details
NCT03903237 Clinical Trial

Herpes Zoster: Risk Factors, Complications and Special Situations

Herpes Zoster Clinical Trial

Official title:
Herpes Zoster: Risk Factors, Complications and Special Situations- a Retrospective Analysis

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT03903237
Other study ID # 2018-02270; sp19Mueller2
Secondary ID
Status Completed
Phase
First received
Last updated
Start date December 20, 2018
Est. completion date February 28, 2019

Study information
Verified date April 2019
Source University Hospital, Basel, Switzerland
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This retrospective analysis is to investigate patients` history and clinical presentation in Herpes Zoster (HZ), Zoster-related complications, post-Zoster neuralgia and Herpes Zoster management in order to improve the management of HZ patients, to refine HZ-vaccination strategies and elucidate cost factors of HZ in in the setting of a university hospital in Switzerland generally and in a dermatology department specifically.

Recruitment information / eligibility
Status Completed
Enrollment 355
Est. completion date February 28, 2019
Est. primary completion date February 28, 2019
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Reports of patients with HZ at University Hospital Basel between 2004-2018

Exclusion Criteria:

- rejection to use patient data

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• retrospective chart review
retrospective report review of HZ patients treated between 2005 and 2018 in the Department of Dermatology at the University Hospital Basel

Locations
Country Name City State
Switzerland Department of Dermatology, University Hospital Basel Basel

Sponsors (1)
Lead Sponsor Collaborator
University Hospital, Basel, Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome
Type Measure Description Time frame Safety issue
Primary Evaluation of patients` history Free text evaluation of patients` history (age, sex, comorbidities, immunosuppression, obesity, human immune deficiency Virus (HIV), profession, current medication, vaccinations, seasonal occurence of HZ, history of Varicella Zoster virus (VZV) infection single time point assessment at baseline
Primary Description of the clinical presentation of HZ Free text description of the clinical presentation of HZ (localisation, dermatomes affected), Zoster-related acute pain single time point assessment at baseline
Primary Evaluation of zoster-related complications Free text evaluation of zoster-related complications (ophthalmic zoster, generalised HZ, Ramsay-Hunt syndrome, zoster meningoencephalitis) single time point assessment at baseline
Primary Evaluation of the herpes zoster management Free text evaluation of the herpes zoster management (local (antiviral) treatment, systemic antiviral and other treatments, number of revisits, average treatment-related costs, hospitalisations (rate, duration) single time point assessment at baseline
Primary Assessment of post-zoster neuralgia Free text assessment of post-zoster neuralgia (annual incidence, treatment options used) single time point assessment at baseline
Primary Evaluation of zoster and pregnancy Free text evaluation of zoster and pregnancy (incidence, time of pregnancy, pregnancy outcomes and complications) single time point assessment at baseline
See also
  Status Clinical Trial Phase
Completed NCT03120364 - Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over Phase 3
Completed NCT01165203 - Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects Phase 2
Recruiting NCT06088745 - A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster Vaccine Phase 3
Completed NCT01385566 - A Study of Intradermal Administration of ZOSTAVAX™ (V211-051 AM2) Phase 1
Completed NCT01137669 - ZOSTAVAX® in Renal Transplant Patients Phase 1
Completed NCT01911065 - T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020 Phase 4
Completed NCT00550745 - ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020) Phase 4
Completed NCT01132729 - Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions N/A
Completed NCT01132716 - Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions N/A
Completed NCT00231816 - A Study of an Investigational Zoster Vaccine in Subjects With a History of Varicella (Chickenpox) Given Concomitantly With Another Vaccine (V211-011) Phase 3
Completed NCT02852876 - Study to Evaluate the Safety and Pharmacokinetics of Single Doses of ASP2151 in Healthy Male Subjects and the Effects of Food Phase 1
Completed NCT05082688 - Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX) Phase 2
Completed NCT04099706 - Treatment of Chronic Postherpetic Pain With Autologous Fat Grafting - A RCT N/A
Active, not recruiting NCT04091451 - A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) Who Had Prior Episode of Shingles Phase 3
Completed NCT02519855 - Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062) Phase 3
Completed NCT04523246 - Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents Early Phase 1
Completed NCT05047770 - A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine Phase 3
Completed NCT03314103 - Efficacy Trial of a Vaccine to Prevent Herpes Zoster in Adults Over 40 Years of Age Phase 3
Completed NCT01527370 - Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025) Phase 3
Completed NCT01954251 - Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older Phase 3